Pranjal Mukhija

So, I just wanted to congratulate the team on the journey that Neuland has been on. A lot of that is now visible in the numbers as well. So, I had a couple of questions. The first question was, sir, in annual report, we're talking about growing interest from customers with larger pipeline. And I think the team also alluded to the same in the concall.

Alright, so sir, this interest is from big pharma companies or like the biotech that we usually deal with?

So, sir, I just wanted to highlight some qualitative data about the new peptide DMFs that we are planning to file. And along with that, like the 6, 7 DM Fs that we are planning to file this year, just some highlights on, some description on what are the areas, what kind of products are we filing for. So, just some information would be really helpful. Thank you.